Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0S9FI
|
|||
| Drug Name |
ICasp9M28z T cell
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Lung cancer [ICD-11: 2C25.0; ICD-9: 162] | Phase 1 | [1] | |
| Malignant pleural effusion [ICD-11: 2D72; ICD-10: C78.2] | Phase 1 | [1] | ||
| Mesothelioma [ICD-11: 2C51.2; ICD-10: C45; ICD-9: 163] | Phase 1 | [1] | ||
| Metastatic malignant neoplasm [ICD-11: 2D50-2E09; ICD-10: C76-C80] | Phase 1 | [1] | ||
| Company |
Memorial Sloan Kettering Cancer Center
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Mesothelin (MSLN) | Target Info | CAR-T-Cell-Therapy | [1] |
| NetPath Pathway | TCR Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02414269) Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.